Skip to main content
SpringerLink
Log in
Book cover

Management of Bleeding Patients pp 103–111Cite as

Hemophilia A, Hemophilia B, Congenital von Willebrand Disease, and Acquired von Willebrand Syndrome

  • Chapter
  • First Online:

  • 937 Accesses

Abstract

Hemophilia A, hemophilia B, and von Willebrand disease can present as bleeding diathesis with an isolated prolonged activated partial thromboplastin time. These conditions are sometimes difficult to differentiate and can occur concurrently, further complicating diagnosis and management. This chapter will discuss hemophilia A and hemophilia B in terms of diagnostic criteria and factor VIII and factor IX physiology. In addition, this chapter will also review both quantitative and qualitative von Willebrand disease. Quantitative von Willebrand disease includes Type 1 and 3 disorders. On the other hand, qualitative disease implies functional defects either in coagulation function (Type 2A, 2B, and 2M disease) or in factor VIII carrier function (Type 2N disease). Pseudo-von Willebrand disease, as its name suggests, is not a true von Willebrand disease, but a platelet glycoprotein Ib receptor gain-of-function disorder which results in laboratory findings that mimic Type 2B disease. Acquired von Willebrand syndrome represents a collection of von Willebrand factor abnormalities that have been associated with a number of known diseases such as aortic valve stenosis and hypothyroidism. The laboratory findings of acquired von Willebrand syndrome often resemble congenital von Willebrand disease subtypes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia. 2015;21(6):731–5.

    Article  CAS  PubMed  Google Scholar 

  2. Di Michele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A. Severe and moderate haemophilia A and B in US females. Haemophilia. 2014;20(2):e136–43.

    Article  PubMed  CAS  Google Scholar 

  3. Radic CP, Rossetti LC, Abelleyro MM, Tetzlaff T, Candela M, Neme D, Sciuccati G, Bonduel M, Medina-Acosta E, Larripa IB, de Tezanos PM, De Brasi CD. Phenotype-genotype correlations in Hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation. J Thromb Haemost. 2015;13(4):530–9. https://doi.org/10.1111/jth.12854. Epub 2015 Mar 14.

    Article  CAS  PubMed  Google Scholar 

  4. Renault NK, Dyack S, Dobson MJ, Costa T, Lam WL, Greer WL. Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur J Hum Genet. 2007;15(6):628–37.

    Article  CAS  PubMed  Google Scholar 

  5. Kentsis A, Anewalt R, Ganguly A, Allen JB, Neufeld EJ. Discordant haemophilia A in male siblings due to a de novo mutation on a familial missense mutant allele. Haemophilia. 2009;15(4):971–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kapsimali Z, Pavlova A, Pergantou H, Adamtziki E, Oldenburg J, Platokouki H. Two de novo factor VIII gene mutations in the family of an isolated severe haemophilia A patient. Haemophilia. 2012;18(1):e3–4.

    Article  CAS  PubMed  Google Scholar 

  7. Castaldo G, D’Argenio V, Nardiello P, Zarrilli F, Sanna V, Rocino A, Coppola A, Di Minno G, Salvatore F. Haemophilia A: molecular insights. Clin Chem Lab Med. 2007;45(4):450–61.

    Article  CAS  PubMed  Google Scholar 

  8. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VIII/coagulant antigen in human liver tissue. Nature. 1983;303(5917):530–2.

    Article  CAS  PubMed  Google Scholar 

  9. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature. 1985;317(6039):729–30.

    Article  CAS  PubMed  Google Scholar 

  10. Choi SJ, Jang KJ, Lim JA, Kim HS. Human coagulation factor VIII domain-specific recombinant polypeptide expression. Blood Res. 2015;50(2):103–8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Venkateswarlu D. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study. BMC Struct Biol. 2010;10:7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Fang H, Wang L, Wang H. The protein structure and effect of factor VIII. Thromb Res. 2007;119(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  13. Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost. 2003;29(1):11–22.

    Article  CAS  PubMed  Google Scholar 

  14. Fay PJ. Factor VIII structure and function. Int J Hematol. 2006;83(2):103–8.

    Article  CAS  PubMed  Google Scholar 

  15. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995;270(15):8546–52.

    Article  CAS  PubMed  Google Scholar 

  16. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991;266(14):8957–62.

    Article  CAS  PubMed  Google Scholar 

  17. Rydz N, Leggo J, Tinlin S, James P, Lillicrap D. The Canadian “National Program for Hemophilia mutation testing” database: a ten-year review. Am J Hematol. 2013;88(12):1030–4.

    Article  PubMed  Google Scholar 

  18. Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375–82.

    Article  CAS  PubMed  Google Scholar 

  19. Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia. 2011;17(2):275–81.

    Article  CAS  PubMed  Google Scholar 

  20. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8(Suppl 2):23–9.

    Article  CAS  PubMed  Google Scholar 

  21. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost. 2000;83(6):844–8.

    Article  CAS  PubMed  Google Scholar 

  22. Goodeve AC, Peake IR. The molecular basis of Hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost. 2003;29(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  23. Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G. Problems and solutions in laboratory testing for Hemophilia. Semin Thromb Hemost. 2013;39(7):816–33.

    Article  PubMed  Google Scholar 

  24. Bolton-Maggs PH, Favaloro EJ, Hillarp A, Jennings I, Kohler HP. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. Haemophilia. 2012;18(Suppl 4):66–72.

    Article  PubMed  Google Scholar 

  25. Jennings I, Kitchen DP, Kitchen S, Woods TA, Walker ID. Investigation of a prolonged APTT. Different approaches taken by laboratories to achieve the same diagnosis. Int J Lab Hematol. 2013;35(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  26. Armstrong E, Hillarp A. Assay discrepancy in mild haemophilia A. Eur J Haematol Suppl. 2014;76:48–50.

    Article  CAS  PubMed  Google Scholar 

  27. Duncan EM, Rodgers SE, McRae SJ. Diagnostic testing for mild Hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays. Semin Thromb Hemost. 2013;39(3):272–82.

    Article  CAS  PubMed  Google Scholar 

  28. Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015;13(7):1184–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gailani D, Geng Y, Verhamme I, Sun MF, Bajaj SP, Messer A, Emsley J. The mechanism underlying activation of factor IX by factor XIa. Thromb Res. 2014;133(Suppl 1):S48–51.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Girolami A, Scandellari R, Scapin M, Vettore S. Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm. 2008;78:281–374.

    Article  CAS  PubMed  Google Scholar 

  31. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52–6.

    Article  CAS  PubMed  Google Scholar 

  32. Gilbert L, Paroskie A, Gailani D, Dabarun MR, Sidonio RF Jr. Haemophilia A carriers experience reduced health-related quality of life. Haemophilia. 2015;21(6):761–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia. 1998;4:836–41.

    Article  CAS  PubMed  Google Scholar 

  34. Graham JB, Miller CH, Reisner HM, Elston RC, Olive JA. The phenotypic range of hemophilia A carriers. Am J Hum Genet. 1976;28:482–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Lusher JM, Mcmillan CW. Severe factor VIII and factor IX deficiency in females. Am J Med. 1978;65:637–48.

    Article  CAS  PubMed  Google Scholar 

  36. Mauser-Bunschoten EP, van Houwelingen JC, Sjamsoedin-Visser EJ, et al. Bleeding symptoms in carriers of haemophilia Aand B. Thromb Haemost. 1988;59:349–52.

    Article  CAS  PubMed  Google Scholar 

  37. Wahlberg T. Carriers and noncarriers of haemophilia A. Evaluation of bleeding symptoms registered by a self-administered questionnaire with binary (no/yes) questions. Thromb Res. 1982;25:415–22.

    Article  CAS  PubMed  Google Scholar 

  38. Wahlberg T, Blomback M, Brodin U. Carries and noncarriers of haemophilia A: multivariate analysis of pedigree data, screening blood coagulation tests and factor VIII variables. Thromb Res. 1982;25:401–14.

    Article  CAS  PubMed  Google Scholar 

  39. Yang MY, Ragni MV. Clinical manifestations and management of labor and delivery in women with factor IX deficiency. Haemophilia. 2004;10:483–90.

    Article  CAS  PubMed  Google Scholar 

  40. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006;32(6):555–65.

    Article  CAS  PubMed  Google Scholar 

  41. Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost. 2005;31(5):577–601.

    Article  CAS  PubMed  Google Scholar 

  42. von Lillicrap D. Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology Am Soc Hematol Educ Program. 2013;2013:254–60.

    Article  PubMed  Google Scholar 

  43. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood. 2009;114(24):5102–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. López JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol. 2004;41(1):15–23.

    Article  PubMed  CAS  Google Scholar 

  45. Pearson JD. The control of production and release of haemostatic factors in the endothelial cell. Baillieres Clin Haematol. 1993;6(3):629–51.

    Article  CAS  PubMed  Google Scholar 

  46. Budde U, Schneppenheim R. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura. Hamostaseologie. 2014;34(3):215–25.

    Article  CAS  PubMed  Google Scholar 

  47. Morrison KA, Jorde UP, Garan AR, Takayama H, Naka Y, Uriel N. Acquired von Willebrand disease during CentriMag support is associated with high prevalence of bleeding during support and after transition to heart replacement therapy. ASAIO J. 2014;60(2):241–2.

    Article  PubMed  Google Scholar 

  48. Huck V, Schneider MF, Gorzelanny C, Schneider SW. The various states of von Willebrand factor and their function in physiology and pathophysiology. Thromb Haemost. 2014;111(4):598–609.

    Article  CAS  PubMed  Google Scholar 

  49. Terraube V, O’Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010;16(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  50. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003;88(6):EREP02.

    PubMed  Google Scholar 

  51. The Diagnosis. Evaluation, and management of von Willebrand disease. 2007. NHLBI von Willebrand Disease Expert Panel.

    Google Scholar 

  52. Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, van Mourik JA. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost. 2008;99(5):916–24.

    CAS  PubMed  Google Scholar 

  53. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10):4979–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol. 1991;50(5):320–2.

    CAS  PubMed  Google Scholar 

  56. Knol HM, Mulder AB, Bogchelman DH, Kluin-Nelemans HC, van der Zee AG, Meijer K. The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. Am J Obstet Gynecol. 2013;209(3):202.e1–7. https://doi.org/10.1016/j.ajog.2013.05.059.

    Article  Google Scholar 

  57. Quiroga T, Goycoolea M, Belmont S, Panes O, Aranda E, Zúñiga P, Pereira J, Mezzano D. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemostasis. 2014;12(8):1238–43.

    Article  CAS  Google Scholar 

  58. Klarmann D, Eggert C, Geisen C, Becker S, Seifried E, Klingebiel T, Kreuz W. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion. 2010;50(7):1571–80.

    Article  CAS  PubMed  Google Scholar 

  59. O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335–41.

    Article  PubMed  Google Scholar 

  60. Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones K, O’Sullican JM, O’Connell NM, Ryan K, White B, Byrne M, Rafferty M, Doyle MM, Nolan M, Preston RJS, Budde U, James P, Paola JD, O’Donnell JS. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130(21):2344–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rovino A, Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(2):4037–44.

    Article  CAS  PubMed  Google Scholar 

  62. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Marco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lilicrap D, Peake IR, Montgomery RR. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016;127(20):2481–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Federici AB, Bucciarelii P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(26):4037–44.

    Article  CAS  PubMed  Google Scholar 

  64. Blenner MA, Dong X, Springer TA. Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib. J Biol Chem. 2014;289(9):5565–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Miller JL, Kupinski JM, Castella A, Ruggeri ZM. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest. 1983;72(5):1532–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol. 2009;121(2–3):145–53.

    Article  CAS  PubMed  Google Scholar 

  67. Miller CH, Kelley L, Green D. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor. Am J Hematol. 1998;58(4):311–8.

    Article  CAS  PubMed  Google Scholar 

  68. Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia a or von Willebrand disease type 1. Thromb Haemost. 1996;76(4):598–602.

    Article  CAS  PubMed  Google Scholar 

  69. Lindsay H, Bergstrom K, Srivaths L. Co-inheritance of mild Hemophilia a and heterozygosity for type 2N von Willebrand disease: a diagnostic and therapeutic challenge. Pediatr Blood Cancer. 2014;61(10):1888–90.

    Article  PubMed  Google Scholar 

  70. Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013;39(2):191–201.

    Article  CAS  PubMed  Google Scholar 

  71. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340(8810):35–7.

    Article  CAS  PubMed  Google Scholar 

  72. Koyama T, Fujimoto K, Shima M. Acquired von Willebrand syndrome associated with Hashimoto’s thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma. Intern Med. 2013;52(23):2661–3.

    Article  PubMed  Google Scholar 

  73. Facon T, Caron C, Courtin P, Wurtz A, Deghaye M, Bauters F, Mazurier C, Goudemand J. Acquired type II von Willebrand’s disease associated with adrenal cortical carcinoma. Br J Haematol. 1992;80(4):488–94.

    Article  CAS  PubMed  Google Scholar 

  74. Federici AB. Acquired von Willebrand syndrome associated with hypothyroidism: a mild bleeding disorder to be further investigated. Semin Thromb Hemost. 2011;37(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  75. World Federation of Hemophilia. Protocols for the treatment of Hemophilia and von Willebrand disease. In: Hemophilia of Georgia, vol. 14. 3rd ed. Montreal: World Federation of Hemophilia; 2008.

    Google Scholar 

  76. Bjorkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Collins PW. Comparative pharmacokinetics of plasma-and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8:730736.

    Article  CAS  Google Scholar 

  77. Bjorkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia. 2013;19:753–7.

    Article  CAS  PubMed  Google Scholar 

  78. Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol. 2015;169:768–76.

    Article  CAS  PubMed  Google Scholar 

  79. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–23.

    Article  CAS  PubMed  Google Scholar 

  80. Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, Pasi J, Baker R, Potts J, Li S. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol. 2014;168:113–23.

    Article  PubMed  CAS  Google Scholar 

  81. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Young GA, Perry DJ, for the International Prophylaxis Study Group (IPSG). Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019;17:567–73.

    Article  PubMed  Google Scholar 

  83. Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVII and factor IX replacement therapies. Semin Thromb Hemost. 2017;43:331–7.

    Article  CAS  PubMed  Google Scholar 

  84. Mensah PK, Gooding R. Surgery in patients with inherited bleeding disorders. Anaesthesia. 2015;70(Suppl 1):112–20. e39–40.

    Article  PubMed  Google Scholar 

  85. Kouides PA. An update on the management of bleeding disorders during pregnancy. Curr Opin Hematol. 2015;22(5):397–405.

    Article  CAS  PubMed  Google Scholar 

  86. Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol. 1997;104(7):803–10.

    Article  CAS  PubMed  Google Scholar 

  87. Haberichter SL. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer. 2006;46(5):547–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Immunology, Division of Transfusion Medicine and Coagulation, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Shiu-Ki Rocky Hui

Authors
  1. Shiu-Ki Rocky Hui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiu-Ki Rocky Hui .

Editor information

Editors and Affiliations

  1. Department of Pathology and Immunology, Division of Transfusion Medicine and Coagulation, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Jun Teruya

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hui, SK.R. (2021). Hemophilia A, Hemophilia B, Congenital von Willebrand Disease, and Acquired von Willebrand Syndrome. In: Teruya, J. (eds) Management of Bleeding Patients. Springer, Cham. https://doi.org/10.1007/978-3-030-56338-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56338-7_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56337-0

  • Online ISBN: 978-3-030-56338-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation